



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Freyne, Eddy J. et al.

Serial No.: 10/596,512

Art Unit: 1624

Filed

: December 15, 2004

Examiner:

For

: PYRIDO-AND PYRIMIDOPYRIMIDINE DERIVATIVES

AS ANTI-PROFILERATIVE AGENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 30, 2006
(Date of Deposit)

Alana G. Kriegsman
(Name of applicant, assignee, or Registered Representative)

/Alana G. Kriegsman/

(Signature)

October 30, 2006

(Date of Signature)

Mail Stop: Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with [] the
first or _second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $\frac{$180.00}{}$ as set forth
in §1.17(p).

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

Statement in Accordance with §1.97(e)
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).
☐ In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
Copies of references listed on the attached Form PTO 1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
☐ Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a) (2).

 \boxtimes There are no listed references which are not in the English language. The relevance of those listed references which are not in the English language is as follows: \boxtimes Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD2170USPCT/AGK. This form is submitted in triplicate. Respectfully submitted, /Alana G. Kriegsman/ Alana G. Kriegsman Reg. No. 41,747 Attorney for Applicants Johnson & Johnson

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1495
DATED: October 30, 2006

.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
of a collection of information unless the state of the collection of information unless the state of the collection of the collectio

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information unless it displays a	valid OMB control number.
Application Number	10/596,512
Filing Date	12/15/2004
First Named Inventor	Eddy J. Freyne
Group Art Unit	1624
Examiner Name	
Attorney Docket Number	PRD2170USPCT

U.S. PATENT DOCUMENTS										
Examiner Initials	Cite			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages of relevant figures appear				
			<u> </u>							
	*									
				-						

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Foreign Patent Document of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite mm-dd-yyyy T^6 Applicant of Cited Document figures appear Initials Office³ Number⁴ KindCode⁵ wο 95/19774 Α1 Warner-Lambert Company 07-27-1995 wo 96/07657 Α1 Dr. Karl Thomae GMBH 03-14-1996 wo 97/32880 09-12-1997 Dr. Karl Thomae GMBH

Examiner Signature /Noble Jarrell/ Date Considered 03/20/2009	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays	a valid OMB control number.
Application Number	10/596,512
Filing Date	12/15/2004
First Named Inventor	Eddy J. Freyne
Group Art Unit	1624
Examiner Name	
Attorney Docket Number	PRD2170USPCT

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	_2
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
Initials*	No.1	publisher, city and/or country where published	
		BROWN et al., "High Throughput Screening", 1997, editors: Devlin, John P., Publishers: Dekker, New York, N.Y., pages	
		317-328.	
		BURKE, Terrence R. Jr., "Protein-tyrosine Kinase Inhibitors", <u>Drugs of The Future</u> , 1992, pages 119-131, Vol. 17, No. 2.	
		DAVIES et al., "Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors", <u>Biochemical Society</u> , 2000 , pages 95-105, Vol. 351.	
		DELIA, Thomas, "Fused Pyrimidines, Part Four, Miscellaneous Fused Pyrimidines: Chapter VI-Pyrimidotriazines.", Heterocyclic Compounds, John Wiley & Sons, Inc., Interscience Publications, pages 261-304. 1991	
	:	DRUKER et al., "Lessons Learned From The Development of An Abl Tyrosine Kinase Inhibitor For Chronic Myelogenous Leukemia" The Journal of Clinical Investigation, January 2000, pages 3-7, Vol. 5, No. 1.	
		ELDER et al., "Overexpression of transforming growth factor alpha in psoriatic epidermis", Science, 1989, pages 811-	
		GENNARO et al. Remington's Pharmaceutical Sciences, 19 th ed., Mack Publishing Company, 1990 , see especially Part 8: Pharmaceutical preparations and their Manufacture.	
		MORIN, Michael J., "From Oncogene to Drug: Development of Small Molecule Tyrosine Kinase Inhibitors as Anti-tumor and Anti-angiogenic Agents", Oncogene, 2000, pages 6574-6583, Vol. 19.	
		NAGAMATSU et al. "Sytheses of 3-Substituted 1-Methyl-6-Phenylpyrimidol5.4-el-1,2.4-triazine-5.7(1H.6H)-diones (6-	
		Phenyl Analogs of Toxoflavin) and Their 4-Oxides, and Evaluation of Antimicrobial Activity of Toxoflavins and Their Analogs.", Chem Pharm Bull., 1993, pages 362-368, Vol 41, No. 2.	
	•	NAGAMATSU et al., "General Syntheses of 1-Alkyltoxoflavin and 8-Alkylfervenulin Derivatives of Biological Significance By The Regioselective Alylation of Reumycin Derivatives And The Rates of Transalkylation From 1-Alkyltoxoflavins Into Nucleophiles.", J. Chem. Soc. Perkin Trans. 1, 2001, pages 130-137.	
		SHAWVER et al., "Smart Drugs: Tyrosine Kinase Inhibitors In Cancer Therapy", Cancer Cells, March 2002, pages 117- 123, Vol 1.	

Examiner Signature /Noble Jarrell/ Date Considered 03/20/2009			
	Examiner	****	Date GR/20/2000
I Signature I //WUNE : IMTE : IMTE IMTE Considered		/Nichio Inrroll/	1 = 1 VUILVILVIU
	Signature	/INDDIE Datien/	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and

Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



SUBMISSION UNDER MPEP 609 D

Application Number	10/596,512
Filing Date	12/15/2004
First Named Inventor	Eddy J. Freyne
Group Art Unit	1624
Examiner Name	
Attorney Docket Number	PRD2170USPCT

Page 1 of 1

- :	 -	U.S. P		OCUMENTS Patent Docum			T	
			0.5	Patent Docum	ient		Bosso Calum	
Examiner	Cite	Name of Patentee or Applicant			Kir	d Code ²	Pages, Columi where relevant p	assages or
Initials	No.1	of Cited Document	Nun	ber	(if	known)	relevant figure	s appear
		· · · · · · · · · · · · · · · · · · ·						
	_						ļ	
		-						
	-	- 1				 		
	_	***				 	 	
				•				
							 	
							 	
		FOREIGI	N PATEN	DOCUMEN	ITS	1		
- 1				Patent Docume		Pages,	Columns, Lines,	
Examiner	Cite	Name of Patentee or					elevant passages elevant figures	6
Initials	No.1	Applicant of Cited Document	Office ³	Number⁴	KindCode ⁵	"	appear	Τ ⁶
	_ INO.						·	
			-	+		 		
						<u> </u>		
						<u> </u>		
			-	+	+	 	·	
				·				
_								
- :		OTHER PRIOR ART - N	ON PATEN	T LITERATUR	RE DOCUMEN	ITS		<u> </u>
		Include name of the author (in C	APITOL L	ETTERS), tit	le of the arti	cle (wher	appropriate),	_,
Examiner 's	Cite No. ¹	title of the item (book, magazine volume-issue number(s	e, journal,	serial, sympo	sium, catalo	g, etc.), (date, page(s),	T ²
s Initials*	INO.	volume-issue number(s	, pablisti	ci, city ariu/0	i country wri	ere hanu	or icu	
		PCT Intl. Search Report, PCT/EP2004/	053501, Ap	ril 28, 2005.				
	_							
				·				

Examiner	/Noble Jarrell/	Date	03/20/200)9	
Signature	//YOUNG OUTFOR	Considered		<i>JU</i>	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./